The I-MASK+ Protocol for COVID-19

In October 2020, the FLCCC Alliance developed a preventive and early outpatient combination treatment protocol for COVID-19 called I-MASK+. It’s centered around ivermectin, a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases.

It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world.

Their medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted their team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see their press release).

Their life-saving  MATH+ Hospital Treatment Protocol for COVID-19 (available in several languages), was created in March 2020 and is intended for hospitalized patients. The recently developed I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19 below is designed for prevention and early outpatient treatment for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved (except ivermectin), inexpensive, readily available, and have been used for decades with well-established safety profiles.

Please download and share their  I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19. (It is currently being translated into several languages).